Skip to Content

Alere among 85 companies to sign Declaration Combating Antimicrobial Resistance in Davos

The Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance was launched at an event at the World Economic Forum in Davos, Switzerland on 21 January 2016.

Alere among 85 companies to sign Declaration Combating Antimicrobial Resistance in Davos

Of the 85 companies that have signed, 11 are diagnostic companies, including Alere. Avi Pelossof, Global President of Infectious Disease at Alere, was quoted about the Declaration:

“Alere is proud to support this declaration and is committed to improving the uptake of rapid point-of-care diagnostics, helping healthcare professionals make the right antibiotic prescribing decision, and addressing the global threat of antimicrobial resistance.”

 The Review on Antimicrobial Resistance further outlines the declaration:

“This was drafted, agreed and signed by 85 companies and nine industry associations from across the global pharmaceutical, diagnostics and biotechnology industries in 18 different countries.

In the Declaration, signatory companies call on governments to work with them to develop new and alternative market structures that provide more dependable and sustainable market models for antibiotics, and to commit the funds needed to implement them. These mechanisms are needed to provide appropriate incentives (coupled with safeguards to support antibiotic conservation) for companies to invest in R&D to overcome the formidable technical and scientific challenges of antibiotic discovery and development.

These include mechanisms to ensure that, where appropriate, the pricing of antibiotics more adequately reflects the benefits they bring; and novel payment models that reduce the link between the profitability of an antibiotic and the volume sold. An integral part of these models is a reduced need for promotional activity by companies.”

The companies that sign the declaration are committing to three main priorities:

  • Work to reduce the development of antimicrobial resistance
  • Invest in R&D to meet public health needs with new innovative diagnostics & treatments
  • Improve access to high-quality antibiotics and ensuring that new ones are available to all

The Declaration is a living document, with signatories free to add or remove their endorsement at any time. It will be reviewed and updated every 2 years to reflect progress and varying priorities.

View the Declaration here [pdf 544KB].

Explore to learn more about rapid diagnostic solutions from Alere and their role in antimicrobial stewardship.

The companies, websites, products and services, and brands referenced and linked to/from this website are not sponsored or endorsed by, or otherwise affiliated with, Abbott or The third-party products and services referenced and linked to/ from this website are included for informational purposes only, and have not been tested or approved by Abbott or Neither Abbott nor makes any representations or warranties regarding third-party products or services, and shall not be liable for any claims arising from those products or services or your use thereof.

Explore Related Content and Videos

Case Study: Influenza

Case Study: Influenza

Which pathway would you choose for your patient?

Accurate Testing for Influenza

Watch how Alere™ i has improved patient care at an urgent care facility.

ews Davos 2017: Committing to Diagnostic Solutions to Tackle Antimicrobial Resistance


Davos 2017: Committing to Diagnostic Solutions to Tackle Antimicrobial Resistance